KR20240019224A - Cd80 및/또는 cd86, 및 ox40l에 결합하는 단백질 - Google Patents
Cd80 및/또는 cd86, 및 ox40l에 결합하는 단백질 Download PDFInfo
- Publication number
- KR20240019224A KR20240019224A KR1020247000142A KR20247000142A KR20240019224A KR 20240019224 A KR20240019224 A KR 20240019224A KR 1020247000142 A KR1020247000142 A KR 1020247000142A KR 20247000142 A KR20247000142 A KR 20247000142A KR 20240019224 A KR20240019224 A KR 20240019224A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- determining region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208478P | 2021-06-08 | 2021-06-08 | |
| US63/208,478 | 2021-06-08 | ||
| US202263343268P | 2022-05-18 | 2022-05-18 | |
| US63/343,268 | 2022-05-18 | ||
| PCT/US2022/032482 WO2022261079A2 (en) | 2021-06-08 | 2022-06-07 | Proteins that bind cd80 and/or cd86, and ox40l |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240019224A true KR20240019224A (ko) | 2024-02-14 |
Family
ID=84426420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247000142A Pending KR20240019224A (ko) | 2021-06-08 | 2022-06-07 | Cd80 및/또는 cd86, 및 ox40l에 결합하는 단백질 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240262922A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4351644A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524880A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240019224A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022290257A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023025553A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3218785A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL309119A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023014695A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202315890A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022261079A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2975057A1 (en) * | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| US9574002B2 (en) * | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
| US20140370012A1 (en) * | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| US9512229B2 (en) * | 2015-03-03 | 2016-12-06 | Kymab Limited | Synergistic combinations of OX40L antibodies for the treatment of GVHD |
| WO2016142768A1 (en) * | 2015-03-10 | 2016-09-15 | Eureka Therapeutics, Inc. | Ror2 antibody |
| AU2016332900C1 (en) * | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| WO2020192709A1 (en) * | 2019-03-27 | 2020-10-01 | Wuxi Biologics (Shanghai) Co., Ltd. | Novel bispecific polypeptide complexes |
-
2022
- 2022-06-07 KR KR1020247000142A patent/KR20240019224A/ko active Pending
- 2022-06-07 AU AU2022290257A patent/AU2022290257A1/en active Pending
- 2022-06-07 BR BR112023025553A patent/BR112023025553A2/pt unknown
- 2022-06-07 CA CA3218785A patent/CA3218785A1/en active Pending
- 2022-06-07 MX MX2023014695A patent/MX2023014695A/es unknown
- 2022-06-07 TW TW111121114A patent/TW202315890A/zh unknown
- 2022-06-07 JP JP2023575897A patent/JP2024524880A/ja active Pending
- 2022-06-07 EP EP22820886.4A patent/EP4351644A4/en active Pending
- 2022-06-07 WO PCT/US2022/032482 patent/WO2022261079A2/en not_active Ceased
- 2022-06-07 IL IL309119A patent/IL309119A/en unknown
-
2023
- 2023-12-06 US US18/530,536 patent/US20240262922A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022290257A1 (en) | 2023-11-30 |
| IL309119A (en) | 2024-02-01 |
| EP4351644A2 (en) | 2024-04-17 |
| WO2022261079A3 (en) | 2023-01-19 |
| MX2023014695A (es) | 2024-01-15 |
| CA3218785A1 (en) | 2022-12-15 |
| AU2022290257A9 (en) | 2023-12-14 |
| JP2024524880A (ja) | 2024-07-09 |
| BR112023025553A2 (pt) | 2024-02-20 |
| WO2022261079A2 (en) | 2022-12-15 |
| US20240262922A1 (en) | 2024-08-08 |
| TW202315890A (zh) | 2023-04-16 |
| EP4351644A4 (en) | 2025-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220251195A1 (en) | Anti-tigit antibodies and their use as therapeutics and diagnostics | |
| KR102926972B1 (ko) | Pd-l1 및 cd137에 결합하는 항체 분자 | |
| KR102943539B1 (ko) | 인터류킨-2 작용제 및 이의 용도 | |
| JP6968872B2 (ja) | 抗Tim−3抗体 | |
| AU2018312251B2 (en) | Anti-CD39 antibodies, compositions comprising anti-CD39 antibodies and methods of using anti-CD39 antibodies | |
| CN104245732B (zh) | 拮抗cd40l的抗体多肽 | |
| CN110506059A (zh) | 特异性结合pd1和lag3的双特异性抗体 | |
| KR20190095941A (ko) | 신규 tnfr 효능제 및 이의 용도 | |
| TW201934583A (zh) | 雙特異性融合多肽及其使用方法 | |
| KR20230147072A (ko) | 인터류킨-2 돌연변이체 및 이의 용도 | |
| JP2024516748A (ja) | EGFRvIII結合タンパク質 | |
| CN116438198A (zh) | 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体 | |
| KR20190117467A (ko) | IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도 | |
| CN121194993A (zh) | Cd8特异性结合蛋白及其应用方法 | |
| US20240262922A1 (en) | Proteins that bind cd80 and/or cd86, and ox40l | |
| HK40111520A (en) | Proteins that bind cd80 and/or cd86, and ox40l | |
| CN117794575A (zh) | 结合cd80和/或cd86,以及ox40l的蛋白质 | |
| RU2826084C2 (ru) | МОЛЕКУЛЫ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТ PD-L1 и CD137 | |
| RU2815066C2 (ru) | Молекулы, связывающие мезотелин и cd137 | |
| JP2024536716A (ja) | PD-L1、CD137及び/又はTGFβへの二重特異性及び三重特異性結合タンパク質ならびにそれらの使用 | |
| JP2026513865A (ja) | がんを処置するためのpd-l1およびcd137に対する多重特異性結合剤 | |
| TW202540189A (zh) | 在組合療法中能夠結合ox40之抗體 | |
| TW202413412A (zh) | 在組合療法中能夠結合到cd27之結合劑 | |
| HK40112413A (en) | BISPECIFIC AND TRISPECIFIC BINDING PROTEINS TO PD-L1, CD137, AND/OR TGFβ AND USES THEREOF |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20240103 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250605 Comment text: Request for Examination of Application |